Product: CCR2 Antibody
Catalog: DF2711
Description: Rabbit polyclonal antibody to CCR2
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 42 kDa,; 42kD(Calculated).
Uniprot: P41597
RRID: AB_2839917

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(88%), Sheep(100%), Rabbit(100%), Dog(88%)
Clonality:
Polyclonal
Specificity:
CCR2 Antibody detects endogenous levels of total CCR2.
RRID:
AB_2839917
Cite Format: Affinity Biosciences Cat# DF2711, RRID:AB_2839917.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

C C chemokine receptor type 2; C C CKR 2; C-C chemokine receptor type 2; C-C CKR-2; CC chemokine receptor type 2; CC CKR 2; CC-CKR-2; CCCKR2; CCR 2; CCR-2; CCR1L; CCR2; CCR2_HUMAN; CCR2A; CCR2B; CCR5L; CD192; CD192 antigen; Chemokine C C motif receptor 2; Chemokine CC Motif Receptor 2; CKR 2; CKR2; CKR2A; CKR2B; CMKBR2; MCP 1 R; MCP-1-R; MCP1 RECEPTOR; MCP1R; Monocyte chemoattractant protein 1 receptor; Monocyte Chemotactic Protein 1 Receptor; Monocyte Chemotactic Protein 1 Receptor;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P41597 CCR2_HUMAN:

Expressed by monocytes and IL2-activated NK cells.

Description:
Receptor for the MCP-1, MCP-3 and MCP-4 chemokines. Transduces a signal by increasing the intracellular calcium ions level. Alternative coreceptor with CD4 for HIV-1 infection.
Sequence:
MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIGAQLLPPLYSLVFIFGFVGNMLVVLILINCKKLKCLTDIYLLNLAISDLLFLITLPLWAHSAANEWVFGNAMCKLFTGLYHIGYFGGIFFIILLTIDRYLAIVHAVFALKARTVTFGVVTSVITWLVAVFASVPGIIFTKCQKEDSVYVCGPYFPRGWNNFHTIMRNILGLVLPLLIMVICYSGILKTLLRCRNEKKRHRAVRVIFTIMIVYFLFWTPYNIVILLNTFQEFFGLSNCESTSQLDQATQVTETLGMTHCCINPIIYAFVGEKFRSLFHIALGCRIAPLQKPVCGGPGVRPGKNVKVTTQGLLDGRGKGKSIGRAPEASLQDKEGA

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Rabbit
100
Horse
88
Dog
88
Xenopus
50
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P41597 As Substrate

Site PTM Type Enzyme
Y139 Phosphorylation O60674 (JAK2)

Research Backgrounds

Function:

Key functional receptor for CCL2 but can also bind CCL7 and CCL12. Its binding with CCL2 on monocytes and macrophages mediates chemotaxis and migration induction through the activation of the PI3K cascade, the small G protein Rac and lamellipodium protrusion (Probable). Also acts as a receptor for the beta-defensin DEFB106A/DEFB106B. Regulates the expression of T-cell inflammatory cytokines and T-cell differentiation, promoting the differentiation of T-cells into T-helper 17 cells (Th17) during inflammation (By similarity). Facilitates the export of mature thymocytes by enhancing directional movement of thymocytes to sphingosine-1-phosphate stimulation and up-regulation of S1P1R expression; signals through the JAK-STAT pathway to regulate FOXO1 activity leading to an increased expression of S1P1R (By similarity). Plays an important role in mediating peripheral nerve injury-induced neuropathic pain (By similarity). Increases NMDA-mediated synaptic transmission in both dopamine D1 and D2 receptor-containing neurons, which may be caused by MAPK/ERK-dependent phosphorylation of GRIN2B/NMDAR2B (By similarity). Mediates the recruitment of macrophages and monocytes to the injury site following brain injury (By similarity).

(Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection.

PTMs:

N-glycosylated.

Sulfation increases the affinity for both monomeric and dimeric CCL2 with stronger binding to the monomeric form. Binding of sulfated CCR2 to CCL2 promotes conversion of CCL2 from dimer to monomer.

Subcellular Location:

Cell membrane>Multi-pass membrane protein.
Note: The chemoattractant receptors are distributed throughout the cell surface; after stimulation with a ligand, such as CCL2, they are rapidly recruited into microdomain clusters at the cell membrane.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed by monocytes and IL2-activated NK cells.

Subunit Structure:

Interacts with ARRB1. Interacts (via extracellular N-terminal region) with beta-defensin DEFB106A/DEFB106B; this interaction may preferentially require specific tyrosine sulfation on CCR2. Interacts with NUP85; the interaction is required for CCR2 clusters formation on the cell membrane and CCR2 signaling.

(Microbial infection) Binds to HIV-1 Tat.

Family&Domains:

Belongs to the G-protein coupled receptor 1 family.

Research Fields

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

References

1). Zhiqiao Gancao Decoction Ameliorates Hyperalgesia in Lumbar Disc Herniation via the CCL2/CCR2 Signaling Pathway. Drug Design, Development and Therapy (PubMed: 37533973) [IF=4.8]

Application: IF/ICC    Species: Rat    Sample:

Figure 4 CCL2 induces the expression of CCR2 and ASIC3 in DRGn, which is inhibited by CCR2 inhibitors and ZQGCD containing serum (A) The cell viability of DRGn. After 12 h pretreatment with RS504393 and ZQGCD containing serum (5%, 10%, and 15%), there was no change in cell viability (P>0.05). After adding CCL2 for 24 h, the viability of unpretreated cells decreased significantly (P0.05). (B) Expression of CCR2 and ASIC3 mRNA in DRGn. (C and D) Expression of CCR2 and ASIC3 proteins in DRGn. **P

Application: IHC    Species: Rat    Sample:

Figure 8 The expression of CCL2/CCR2 pathway in the intervertebral disc of LDH rats was increased, but CCR2 inhibitors or ZQGCD inhibited this expression. (A and B) Representative images (magnification: 40x) and semi-quantitative histogram of immunohistochemical staining of CCL2 protein of intervertebral disc. (C and D) Representative images (magnification: 40x) and semi-quantitative histogram of immunohistochemical staining of CCR2 protein of intervertebral disc.

Application: WB    Species: Rat    Sample:

Figure 9 CCL2/CCR2 pathway and ASIC3 were highly in DRG of LDH rats expressed but inhibited by CCR2 inhibitor or ZQGCD. (A) Bar graphs showing the expression levels of CCL2 and CCR2 mRNA in DRG. (B and C) Immunoblot and bar graphs showing the expression levels of CCL2 and CCR2 in DRG.

2). C-C chemokine receptor type 2-overexpressing exosomes alleviated experimental post-stroke cognitive impairment by enhancing microglia/macrophage M2 polarization. World Journal of Stem Cells (PubMed: 32184939) [IF=4.1]

Application: WB    Species: human    Sample: HUC-MSCsCtrlvs HUC-MSCsCCR2

Figure 1 |Human umbilical cord mesenchymal stem cellsCCR2 load the C-C chemokine receptor type 2 receptor into their exosomes. A, B: Flow cytometryanalysis of the C-C chemokine receptor type 2 (CCR2) receptor on human umbilical cord mesenchymal stem cells (HUC-MSCs)Ctrl and HUC-MSCsCCR2, n = 3, cP <0.001; C: CCR2 mRNA expression in HUC-MSCsCtrlvs HUC-MSCsCCR2, n = 3, cP < 0.001; D: Western blotting analysis for the quantification of the CCR2 expressionin HUC-MSCsCtrlvs HUC-MSCsCCR2, n = 3

3). Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio. Naunyn-Schmiedeberg's archives of pharmacology (PubMed: 32524150) [IF=3.6]

Application: WB    Species: rat    Sample: liver

Fig. 4 |Berberine modulates intrahepatic CCR2+ inflammatory cells. a, bThe protein level of CCR2 was measured by Western blot analysis and normalized by GAPDH expression

4). Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway. BMC IMMUNOLOGY (PubMed: 32429849) [IF=3.0]

Application: WB    Species: rat    Sample: liver

Fig. 5 |The protein levels of Angptl2, Foxo1, NF-κB, p-NF-κB and CCR2 were measured by Western blot analysis and normalized by GAPDH expression. Data are presented as mean ± SD from eight rats. **P < 0.01,* P < 0.05.n = 8/group

5). Resveratrol reduces the inflammatory response in adipose tissue and improves adipose insulin signaling in high-fat diet-fed mice. PeerJ (PubMed: 29967759) [IF=2.7]

Application: WB    Species: mouse    Sample: SAT(subcutaneous adiposet issue)

Figure 7 |Effects of resveratrol treatment on the protein expression of CCR2, IRS-1, pAkt (phosphorylation at Ser 473) and GLUT4 in SAT and VAT. (A) Western blots of CCR2 and insulin signaling molecules in SAT

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.